FDA approved expanded indication for use of Boostrix Tdap vaccine in people ages 10-64 years
On Dec. 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium).
Boostrix was licensed for use in persons aged 10–64 years as a single-dose booster immunization; the vaccine initially was licensed for persons aged 10–18 years.
Tags:
Source: U.S. Centers for Disease Control and Prevention
Credit:
